Literature DB >> 17323135

Prospective study of supplemental vitamin K therapy in patients on oral anticoagulants with unstable international normalized ratios.

Sarah K Ford1, Caron P Misita, Betsy Bryant Shilliday, Robert M Malone, Charity G Moore, Stephan Moll.   

Abstract

BACKGROUND: It is not known whether patients on oral vitamin K antagonists who have unstable INRs achieve more stable INRs with daily vitamin K supplementation. We sought to determine whether vitamin K supplementation may decrease INR variability in patients with a history of unstable INRs, how soon the INR decreases after vitamin K therapy is initiated, the time to reach a therapeutic INR after vitamin K initiation, and how much of an increase in oral anticoagulant dose is needed to maintain the INR in the desired range.
METHODS: This is a prospective open label crossover study of patients on warfarin with a history of fluctuating INRs. A 9 week observation phase was followed by an 8 week period with patients receiving 500 microg of oral vitamin K daily. INRs were determined once weekly with a home point of care monitoring instrument.
RESULTS: Vitamin K supplementation led to a decrease in INR variability in five of the nine patients studied (56%). INR decrease occurred 2-7 days after initiation of vitamin K. Therapeutic INRs were achieved 2-35 days after vitamin K therapy was initiated and an increase in warfarin dose of 6-95% was required to bring the INR back into the therapeutic range.
CONCLUSIONS: INR fluctuations may decrease in selected patients with unstable INRs who receive vitamin K supplementation. A study with a larger sample size and longer follow-up period is needed. The results of the present study can help design such a study.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17323135     DOI: 10.1007/s11239-007-0014-z

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   5.221


  5 in total

1.  Role of dietary vitamin K intake in chronic oral anticoagulation: prospective evidence from observational and randomized protocols.

Authors:  Viviane Franco; Carisi A Polanczyk; Nadine Clausell; Luis E Rohde
Journal:  Am J Med       Date:  2004-05-15       Impact factor: 4.965

2.  Vitamin K supplementation can improve stability of anticoagulation for patients with unexplained variability in response to warfarin.

Authors:  Elizabeth Sconce; Peter Avery; Hilary Wynne; Farhad Kamali
Journal:  Blood       Date:  2006-11-16       Impact factor: 22.113

3.  Low-dose vitamin K to augment anticoagulation control.

Authors:  Alicia M Reese; Lisa E Farnett; Roger M Lyons; Bhavin Patel; Laura Morgan; Henry I Bussey
Journal:  Pharmacotherapy       Date:  2005-12       Impact factor: 4.705

4.  Patients with unstable control have a poorer dietary intake of vitamin K compared to patients with stable control of anticoagulation.

Authors:  Elizabeth Sconce; Tayyaba Khan; Jennifer Mason; Faye Noble; Hilary Wynne; Farhad Kamali
Journal:  Thromb Haemost       Date:  2005-05       Impact factor: 5.249

5.  The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

Authors:  Jack Ansell; Jack Hirsh; Leon Poller; Henry Bussey; Alan Jacobson; Elaine Hylek
Journal:  Chest       Date:  2004-09       Impact factor: 9.410

  5 in total
  11 in total

Review 1.  Practical issues with vitamin K antagonists: elevated INRs, low time-in-therapeutic range, and warfarin failure.

Authors:  Andrea Lee; Mark Crowther
Journal:  J Thromb Thrombolysis       Date:  2011-04       Impact factor: 2.300

Review 2.  Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Walter Ageno; Alexander S Gallus; Ann Wittkowsky; Mark Crowther; Elaine M Hylek; Gualtiero Palareti
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

3.  Case studies in anticoagulation management.

Authors:  Wendy A Leong
Journal:  J Thromb Thrombolysis       Date:  2007-10-01       Impact factor: 2.300

Review 4.  Anticoagulation: where we are and where we need to go.

Authors:  Geoffrey D Barnes; James B Froehlich
Journal:  J Thromb Thrombolysis       Date:  2008-07-18       Impact factor: 2.300

5.  Ezetimibe enhances and stabilizes anticoagulant effect of warfarin.

Authors:  Takehiro Hashikata; Minako Yamaoka-Tojo; Ryota Kakizaki; Teruyoshi Nemoto; Kazuhiro Fujiyoshi; Sayaka Namba; Lisa Kitasato; Takuya Hashimoto; Shunsuke Ishii; Ryo Kameda; Takao Shimohama; Taiki Tojo; Junya Ako
Journal:  Heart Vessels       Date:  2016-04-06       Impact factor: 2.037

6.  Supplemental vitamin K improves the stability of anticoagulation in a patient with low tissue stores of vitamin K secondary to coeliac disease.

Authors:  Cassandra Emily Janeczko; Karen Sweeney; G Connaghan
Journal:  BMJ Case Rep       Date:  2009-05-17

Review 7.  Warfarin and vitamin K intake in the era of pharmacogenetics.

Authors:  Yael Lurie; Ronen Loebstein; Daniel Kurnik; Shlomo Almog; Hillel Halkin
Journal:  Br J Clin Pharmacol       Date:  2010-08       Impact factor: 4.335

8.  Does vitamin K supplementation improve vitamin K antagonist therapy? A case report and update of the literature.

Authors:  Sahar Vanessa Amiri; Johannes Jakobsen Sidelmann; Mustafa Vakur Bor
Journal:  J Cardiol Cases       Date:  2022-01-13

9.  Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects.

Authors:  Charles Frost; Jessie Wang; Sunil Nepal; Alan Schuster; Yu Chen Barrett; Rogelio Mosqueda-Garcia; Richard A Reeves; Frank LaCreta
Journal:  Br J Clin Pharmacol       Date:  2013-02       Impact factor: 4.335

Review 10.  Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays.

Authors:  Jonathan Douxfils; Anne Tamigniau; Bernard Chatelain; Catherine Goffinet; Jean-Michel Dogné; François Mullier
Journal:  Thromb J       Date:  2014-11-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.